【摘 要】
：
目的: Controlled trials have shown that erythropoiesis-stimulating agents (ESAs) raise hemoglobin (Hb)and reduce transfusions in patients with CIA.In a few trials, increased mortality and/or tumor progr
【机 构】
：
Sun Yat-Sun University Cancer Center, East Guangzhou, China
【出 处】
：
第十七届全国临床肿瘤学大会暨2014年CSCO学术年会
论文部分内容阅读
目的: Controlled trials have shown that erythropoiesis-stimulating agents (ESAs) raise hemoglobin (Hb)and reduce transfusions in patients with CIA.In a few trials, increased mortality and/or tumor progression were suggested with ESA use although some of the trials were not designed to assess survival/mortality.Many other trials have not reported an association with worse outcomes.The purpose of this trial is to evaluate long-term safety of darbepoetin alfa in NSCLC patients with CIA.
其他文献
Objective: This study was to evaluate the association between single-nucleotide polymorphisms (SNP) in VTI1A gene and the susceptibility to lung cancer in never-smoking Chinese patients, and investiga
Objective:A, an oral, irreversible ErbB family blocker, was compared with GC in 364 Asian pts with EGFR mut positive NSCLC, including 327 pts from China.PFS was significantly prolonged with A vs GC in
Objective: Preclinical models have shown that recombinant human endostatin (Endostar) can transiently normalize the tumor vasculature to make it more efficient for oxygen delivery, which provides a tr
Objective: Platinum based doublet chemotherapy is standard treatment for treatment na(i)ve advanced NSCLC pts, although molecularly targeted therapy can improve outcome of selected patients who harbor
目的:近年来血液循环肿瘤细胞(Circulating tumor cell,CTC)检测已成为监测肿瘤病情、评价肿瘤治疗疗效的新方法.本研究旨在通过免疫磁珠负向富集技术结合靶向PCR技术(LT-PCR)的方法,检测肺癌患者外周血中CTC的灵敏度及特异性;比较CTC与血清肿瘤标志物检测肺部良恶性疾病的灵敏度及特异性;初步评价在晚期非小细胞肺癌(non-small cell lung cancer,N
目的:细胞毒性T淋巴细胞相关抗原(cytotoxic T lymphocyte associated antigen-4,CTLA-4)、程序坏死因子(programmed death 1,PD-1)和程序坏死因子配体(programmed death ligand 1,PD-L1)属于immune checkpoints蛋白家族,是目前肿瘤免疫靶向治疗中最受关注的分子靶标.文献己报道CTLA-4
目的:脑转移为非小细胞肺癌(NSCLC)患者的常见并发症,自然病程通常为4-11周.全脑放疗(WBRT)将此类患者的生存期延长至3-6个月,但有效率仅为25-30％.表皮生长因子受体(EGFG)酪氨酸激酶抑制剂(TKI)的应用,进一步延长了EGFR突变阳性脑转移患者的生存期.然而高达11-44％的脑转移灶对TKI抗拒.本试验通过系统性回顾EGFR突变阳性、无症状脑转移的NSCLC患者的临床资料,分
Objective: HOTAIR, a long intervening non-coding RNA (lincRNA), associates with the Polycomb Repressive Complex 2 (PRC2) and is reported to reprogram chromatin organization and promote tumor progressi
目的:探讨18 F-脱氧葡萄糖(fluorodeoxyglucose,FDG)正电子发射断层扫描/计算机体层摄影(positron emission tomography/computed tomography,PET/CT)对预测Ⅰ期非小细胞肺癌(non-small lung cancer,NSCLC)术后复发风险的作用.方法:回顾性分析182例术前行PET/CT检查的Ⅰ期NSCLC患者,对性别
目的:探讨局限期小细胞肺癌放化综合治疗的疗效和影响预后的因素.方法:回顾分析我院1996～2006年收治的放疗/化疗综合治疗的335例局限期小细胞肺癌患者,中位年龄54岁(25～85岁),男253例,女82例.KPS≥80分241例,＜80分93例.有吸烟史者213例,无吸烟史者120例.全组根据AJCC第7版重新分期,重新分期后ⅠA期2例,ⅠB期11例,ⅡA期6例,ⅡB期27例,ⅢA期168例,